2,647
Views
6
CrossRef citations to date
0
Altmetric
RESEARCH ARTICLE

Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1α

&
Pages 171-182 | Received 02 Nov 2020, Accepted 24 Dec 2020, Published online: 11 Jan 2021

References

  • Alanazi SA, Alanazi F, Haq N, et al. (2020). Lipoproteins-nanocarriers as a promising approach for targeting liver cancer: present status and application prospects. Curr Drug Deliv 17:826–844.
  • An L, Zeng HM, Zheng RS, et al. (2019). [Liver cancer epidemiology in China, 2015]. Zhonghua Zhong Liu Za Zhi 41:721–7.
  • Chu KF, Dupuy DE. (2014). Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 14:199–208.
  • Chu Q, Jiang Y, Zhang W, et al. (2016). Pyroptosis is involved in the pathogenesis of human hepatocellular carcinoma. Oncotarget 7:84658–65.
  • Cui H-X, Hu Y-N, Li J-W, et al. (2018). Preparation and evaluation of antidiabetic agents of berberine organic acid salts for enhancing the bioavailability. Molecules 24:103.
  • Dubbelboer IR, Pavlovic N, Heindryckx F, et al. (2019). Liver cancer cell lines treated with doxorubicin under normoxia and hypoxia: cell viability and oncologic protein profile. Cancers 11:1024.
  • Elsheikh MA, Elnaggar YSR, Hamdy DA, Abdallah OY. (2018). Novel cremochylomicrons for improved oral bioavailability of the antineoplastic phytomedicine berberine chloride: optimization and pharmacokinetics. Int J Pharm 535:316–24.
  • Forner A, Reig M, Bruix J. (2018). Hepatocellular carcinoma. Lancet 391:1301–14.
  • Fu J, Wang HY. (2018). Precision diagnosis and treatment of liver cancer in China. Cancer Lett 412:283–8.
  • Govaert KM, Emmink BL, Nijkamp MW, et al. (2014). Hypoxia after liver surgery imposes an aggressive cancer stem cell phenotype on residual tumor cells. Ann Surg 4:750–9.
  • Huang YZ, Wang KY, Gu CG, et al. (2018). Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib. Onco Rep 40:1525–32.
  • Jacobs A. (2015). Radiofrequency ablation for liver cancer. Radiol Technol 86:645–64.
  • Knox JJ, Cleary SP, Dawson LA. (2015). Localized and systemic approaches to treating hepatocellular carcinoma. J Clin Oncol 33:1835–44.
  • Li GF, Cai CF, Ren TY, Tang X. (2014). Development and application of a UPLC-MS/MS method for the pharmacokinetic study of 10-hydroxy camptothecin and hydroxyethyl starch conjugate in rats. J Pharm Biomed Anal 88:345–53.
  • Li GF, Yang F, Liu M, et al. (2016). Development and application of a UPLC-MS/MS method for simultaneous determination of fenofibric acid and berberine in rat plasma: application to the drug-drug pharmacokinetic interaction study of fenofibrate combined with berberine after oral administration in rats. Biomed Chromatogr 30:1075–82.
  • Li GF, Zhao MM, Zhao LM. (2016). Well-defined hydroxyethyl starch-10-hydroxy camptothecin super macromolecule conjugate: cytotoxicity, pharmacodynamics research, tissue distribution test and intravenous injection safety assessment. Drug Deliv 23:2860–8.
  • Li J, Li O, Kan M, et al. (2015). Berberine induces apoptosis by suppressing the arachidonic acid metabolic pathway in hepatocellular carcinoma. Mol Med Rep 12:4572–7.
  • Li M, Zhang M, Zhang ZL, et al. (2017). Induction of apoptosis by berberine in hepatocellular carcinoma HepG2 Cells via downregulation of NF-κB. Onco Rep 25:233–9.
  • Li SX, Yin GF, Pu XM, et al. (2019). A novel tumor-targeted thermosensitive liposomal cerasome used for thermally controlled drug release. Int J Pharm 570:118660.
  • Li XD, Wang Z, Wang XR, et al. (2019). Berberine-loaded janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition. Int J Nanomedicine 14:3967–82.
  • Luo LF, Chen QY, Gong HY, et al. (2018). Capacity of cholesteryl hemisuccinate in ion pair/phospholipid complex to improve drug-loading, stability and antibacterial activity of clarithromycin intravenous lipid microsphere. Colloids Surf B Biointerfaces 172:262–71.
  • Luo LF, Wang XZ, Chen QY, et al. (2017). A parenteral docetaxel-loaded lipid microsphere with decreased 7-epidocetaxel conversion in vitro and in vivo. Eur J Pharm Sci 109:638–49.
  • Mirhadi E, Rezaee M, Nikouei BM. (2018). Nano strategies for berberine delivery, a natural alkaloid of berberis. Biomed Pharmacother 104:465–73.
  • Pan Y, Shao D, Zhao YW, et al. (2017). Berberine reverses hypoxia-induced chemoresistance in breast cancer through the inhibition of AMPK- HIF-1α. Int J Biol Sci 13:794–803.
  • Song L, Luo Y, Wang X, et al. (2019). Exploring the active mechanism of berberine against HCC by systematic pharmacology and experimental validation. Mol Med Rep 20:4654–64.
  • Teng F, Yang H, Li GF, et al. (2014). Parenteral formulation of larotaxel lipid microsphere tackling poor solubility and chemical instability. Int J Pharm 460:212–9.
  • Wang G-Y, Lv Q-H, Dong Q, et al. (2009). Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice. J Asian Nat Prod Res 11:219–28.
  • Wang T, Wang N, Song H, et al. (2011). Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine. Eur J Pharm Sci 44:127–35.
  • Yip NKY, Ho WS. (2013). Berberine induces apoptosis via the mitochondrial pathway in liver cancer cells. Oncol Rep 30:1107–12.
  • Zhang ZH, Chen Y, Deng J, et al. (2014). Solid dispersion of berberine-phospholipid complex/TPGS 1000/SiO2: preparation, characterization and in vivo studies. Int J Pharm 465:306–16.